ConductScience.org, home

Paper36264792

Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators.

Fiedorczuk K and 1 other. Science, 2022. Cited by 152 papers, by iCite.

Cite this record

ConductScience Library. Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators. Papers, record 36264792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36264792

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators.
PubMed
Journal
Science
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
152
iCite
Relative citation ratio, by iCite
12.1
iCite
Revised in PubMed
2026-01-27
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fiedorczuk KKarolhttps://orcid.org/0000-0001-7439-0222
2Chen JJuehttps://orcid.org/0000-0003-2075-4283

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cystic Fibrosis Transmembrane Conductance RegulatorMajor topic
PhenylalanineMajor topic
Sequence DeletionMajor topic
Cystic FibrosisMajor topic
Cryoelectron Microscopy
Humans
Protein Conformation
Drug Synergism
Aminophenols
Drug Combinations
Indoles
Pyrazoles
Pyridines
Quinolines
Benzodioxoles
Quinolones

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Howard Hughes Medical InstituteUnited StatesPubMed

Source PubMed

Download CSV of grants

References71

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115729345CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains.Nature2005https://conductscience.org/library/papers/15729345PubMed
215264254UCSF Chimera--a visualization system for exploratory research and analysis.J Comput Chem2004https://conductscience.org/library/papers/15264254PubMed
322138491CFTR: folding, misfolding and correcting the ΔF508 conformational defect.Trends Mol Med2012https://conductscience.org/library/papers/22138491PubMed
416339147Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis.J Biol Chem2006https://conductscience.org/library/papers/16339147PubMed
520667826The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis.J Biol Chem2010https://conductscience.org/library/papers/20667826PubMed
623104983Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein.FASEB J2013https://conductscience.org/library/papers/23104983PubMed
734995514Mechanism of CFTR correction by type I folding correctors.Cell2022https://conductscience.org/library/papers/34995514PubMed
833775603Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.J Cyst Fibros2021https://conductscience.org/library/papers/33775603PubMed
923666117Mechanism-based corrector combination restores ΔF508-CFTR folding and function.Nat Chem Biol2013https://conductscience.org/library/papers/23666117PubMed
1028340353Molecular Structure of the Human CFTR Ion Channel.Cell2017https://conductscience.org/library/papers/28340353PubMed
1111600681A cluster of negative charges at the amino terminal tail of CFTR regulates ATP-dependent channel gating.J Physiol2001https://conductscience.org/library/papers/11600681PubMed
122475911Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.Science1989https://conductscience.org/library/papers/2475911PubMed
1328735752Conformational Changes of CFTR upon Phosphorylation and ATP Binding.Cell2017https://conductscience.org/library/papers/28735752PubMed
1430334692VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.N Engl J Med2018https://conductscience.org/library/papers/30334692PubMed
151718606Nucleoside triphosphates are required to open the CFTR chloride channel.Cell1991https://conductscience.org/library/papers/1718606PubMed
1620590134The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface.Biochemistry2010https://conductscience.org/library/papers/20590134PubMed
1733303536Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.Eur Respir J2021https://conductscience.org/library/papers/33303536PubMed
1815528182Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.J Biol Chem2005https://conductscience.org/library/papers/15528182PubMed
199920908Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal.J Biol Chem1999https://conductscience.org/library/papers/9920908PubMed
2027469176Background and Epidemiology.Pediatr Clin North Am2016https://conductscience.org/library/papers/27469176PubMed

See all 71 referencesDownload CSV of references

Cited by107

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 152 citations.

PMIDTitleJournalYearIn PapersSource
42707060Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis.iScience2026https://conductscience.org/library/papers/42707060PubMed
42675037Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42675037PubMed
42654157Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research.Pharmaceutics2026https://conductscience.org/library/papers/42654157PubMed
42601390Triple potentiator combinations increase the functional correction of several CFTR gating mutants.NPJ Drug Discov2026https://conductscience.org/library/papers/42601390PubMed
42589573Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features.Int J Mol Sci2026https://conductscience.org/library/papers/42589573PubMed
42582698Unique fluoroalkyl substituents: is there life after CF3?Chem Sci2026https://conductscience.org/library/papers/42582698PubMed
42488778Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases.Isr J Chem2024https://conductscience.org/library/papers/42488778PubMed
42403151Regulation of CFTR stability at the plasma membrane-Mechanisms and therapeutic opportunities in cystic fibrosis.FEBS Lett2026https://conductscience.org/library/papers/42403151PubMed
42282787Profiling the CFTR Variant Selectivity and Off-Target Interactions of VX-121.bioRxiv2026https://conductscience.org/library/papers/42282787PubMed
42182326De novo design of transmembrane accessory subunits for fold stabilization and expansion.bioRxiv2026https://conductscience.org/library/papers/42182326PubMed
42085239Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.Am J Respir Crit Care Med2026https://conductscience.org/library/papers/42085239PubMed
41998105A cell-permeable nanobody to restore F508del cystic fibrosis transmembrane conductance regulator activity.Nat Chem Biol2026https://conductscience.org/library/papers/41998105PubMed
41920076Altered functional interactions between CFTR disease mutants ΔF508 and G551D and the protein kinase A catalytic subunit.J Physiol2026https://conductscience.org/library/papers/41920076PubMed
41915736Single-molecule dissection of CFTR folding defects and pharmacological rescue.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41915736PubMed
41898631Distinct CFTR Mutation Spectrum and Atypical Clinical Presentations in Chinese Patients with Cystic Fibrosis.Int J Mol Sci2026https://conductscience.org/library/papers/41898631PubMed
41576103Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41576103PubMed
41482647Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis.Ther Adv Respir Dis2026https://conductscience.org/library/papers/41482647PubMed
41379933General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants.Elife2025https://conductscience.org/library/papers/41379933PubMed
41258017In vivo conformational space and defects of misfolded CFTR variants by covalent protein painting.Nat Commun2025https://conductscience.org/library/papers/41258017PubMed
41235117Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.Front Pharmacol2025https://conductscience.org/library/papers/41235117PubMed

See all 107 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CFTR1080PubTator's text mininghttps://conductscience.org/library/genes/1080

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36264792

GET https://conductscience.org/api/papers/v1/36264792/references?page=2